Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (NCT03583710)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high risk of coming back (recurrence). Cortisol can cause the growth of adrenocortical tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or mitotane with cisplatin and etoposide after surgery works better in treating patients with adrenocortical carcinoma.
Who can join: Review the eligibility criteria below.
Location: University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Siteman Cancer Center at Washington University — St Louis, Missouri
- M D Anderson Cancer Center — Houston, Texas
- Institut de Cancérologie de l'Ouest (ICO) — Angers,
- CHU Angers, Hôpital Larrey — Angers,
- CHU Besançon, Hôpital Jean Minjoz — Besançon,
- CHU Brest, Hôpital La Cavale Blanche — Brest,
- Centre Georges François Leclerc — Dijon,
- Lyon HCL — Lyon,
- HCL Hôpital Louis Pradel — Lyon,
- Marseille Hôpital Nord — Marseille,
- Marseille Hôpital de la Conception — Marseille,
- CHU Nantes, Hôpital René et Guillaume Laënnec — Nantes,
- CHU Nantes, Hôpital René et Guillaume Laënnec — Nantes,
- Hôpital Cochin, AP-HP — Paris,
- Hôpital Cochin, AP-HP — Paris,
- Hôpital Cochin — Paris,
- Hôpital COCHIN — Paris,
- CHU Bordeaux - Hôpital Haut Lévèque — Pessac,
- CHU Poitiers — Poitiers,
- CHU Reims — Reims,
- HUS, Hôpital Hautepierre — Strasbourg,
- Strasbourg HUS Hautepierre — Strasbourg,
- CHU Toulouse, Hôpital Larrey — Toulouse,
- CHU Toulouse, Hôpital Rangueil — Toulouse,
📞 Contact the Study Coordinator
Phone: (713) 792-2841
Email: jvarghese@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All ENSAT Stage I Adrenal Cortex Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.